Alberto Grignolo

Alberto has over 36 years of experience as a regulatory and drug development professional and corporate executive, including 26 years as a consultant to pharmaceutical and biotechnology companies. He established the firm’s Japan Consulting Services during a two-year assignment in Tokyo.

Work Experience

Alberto is a past chairman of the board of the Regulatory Affairs Professionals Society (RAPS), and was the recipient of the 1995 Richard E. Greco Professional of the Year Award from RAPS. He has been an active member of the Drug Information Association (DIA) since 1984, served on the DIA Board from 2000 until 2004, was the chair of the 2007 DIA Annual Meeting and has been an instructor on the DIA Regulatory Training faculty for nearly two decades, teaching in the US, Europe, Australia, Japan, Korea and China. 

He was a member (2008-2011) of the first Executive Committee of the Clinical Trials Transformation Initiative (CTTI), a public private partnership between the FDA and Duke University aiming to increase the quality and efficiency of clinical trials. He was an expert adviser to the Institute of Medicine’s “Committee on Assessing the System for Protecting Human Research Participants” in 2000-2002, received the 2008 Lifetime Achievement Award from the GCP Journal and was recognized as one of the 100 Most Inspiring People in the Life-Sciences Industry in 2008 by the readers of PharmaVOICE. 

Prior to joining Parexel, Alberto served as president of FIDIA Pharmaceutical Corporation and held regulatory positions at SmithKline & French Laboratories. 

Alberto has been a frequent speaker, program chair, session chair and instructor at more than 120 international conferences, seminars, workshops and courses on drug development and regulatory affairs and has published more than 35 professional and scientific articles. He is the editor of DIA Global Forum magazine, received DIA’s Global Inspire Award (Global Connector) in 2015 and was named a Fellow of DIA in 2017.

Education

Alberto earned his undergraduate degree at Duke University, his doctorate in experimental psychology from the University of North Carolina and conducted postdoctoral research in neuropharmacology at Duke University Medical Center.